05 / 25 / 22

SMPS Legal advised Sanfer Farma from a tax perspective regarding the acquisition of the majority stake in Probiomed, S.A. de C.V.


MEXICO CITY, MEXICO, May 25th, 2022 –  Sanfer Farma, one of the largest pharmaceutical groups in Mexico and Latin America, announced the acquisition of the majority stake in Probiomed, S.A. de C.V., a manufacturing company of biotechnology-based pharmaceutical products.

SMPS Legal advised Sanfer Farma from a tax perspective on the acquisition of Probiomed, including the tax consequences of the insolvency agreement to which Probiomed was a party.

The acquisition of Probiomed represents for the Mexican company a triumphant entry into the modern pharmaceutical sector and a continuous development in the market throughout Latin America, as well as other regions.

More News